Compare TSN & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSN | ROIV |
|---|---|---|
| Founded | 1935 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Meat/Poultry/Fish | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6B | 20.7B |
| IPO Year | 1994 | 2021 |
| Metric | TSN | ROIV |
|---|---|---|
| Price | $64.15 | $28.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | ★ $66.90 | $28.94 |
| AVG Volume (30 Days) | 2.1M | ★ 4.4M |
| Earning Date | 05-04-2026 | 05-28-2026 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $54,441,000,000.00 | $29,053,000.00 |
| Revenue This Year | $5.74 | N/A |
| Revenue Next Year | $1.14 | $744.61 |
| P/E Ratio | $267.46 | ★ N/A |
| Revenue Growth | ★ 2.12 | N/A |
| 52 Week Low | $50.56 | $10.58 |
| 52 Week High | $66.24 | $30.33 |
| Indicator | TSN | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 51.34 | 48.61 |
| Support Level | $62.32 | $27.00 |
| Resistance Level | $65.59 | $30.26 |
| Average True Range (ATR) | 1.34 | 0.90 |
| MACD | -0.14 | -0.14 |
| Stochastic Oscillator | 41.09 | 31.41 |
Tyson Foods is a protein-focused food producer, selling raw chicken, beef, pork, and prepared foods. Chicken and beef are its two largest segments, composing about 40% and 30% of sales, respectively. Prepared foods constituted 18% of fiscal 2025 sales and include brands like Tyson, Jimmy Dean, Hillshire Farm, Ball Park, and Sara Lee. However, most of these are in product categories rife with competition where Tyson does not have a massive market share lead. Tyson sells some products overseas, but the international segment accounts for just 4% of total revenue. The company is an active acquirer, with more recent years' purchases focused on international and food-service markets.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.